Department of Molecular Microbiology and Immunology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.
Johns Hopkins Malaria Institute, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.
EMBO Mol Med. 2021 Apr 9;13(4):e11796. doi: 10.15252/emmm.201911796. Epub 2021 Mar 22.
Malaria infection starts with the injection of Plasmodium sporozoites into the host's skin. Sporozoites are motile and move in the skin to find and enter blood vessels to be carried to the liver. Here, we present the first characterization of P. falciparum sporozoites in vivo, analyzing their motility in mouse skin and human skin xenografts and comparing their motility to two rodent malaria species. These data suggest that in contrast to the liver and blood stages, the skin is not a species-specific barrier for Plasmodium. Indeed, P. falciparum sporozoites enter blood vessels in mouse skin at similar rates to the rodent malaria parasites. Furthermore, we demonstrate that antibodies targeting sporozoites significantly impact the motility of P. falciparum sporozoites in mouse skin. Though the sporozoite stage is a validated vaccine target, vaccine trials have been hampered by the lack of good animal models for human malaria parasites. Pre-clinical screening of next-generation vaccines would be significantly aided by the in vivo platform we describe here, expediting down-selection of candidates prior to human vaccine trials.
疟疾感染始于疟原虫孢子进入宿主皮肤。孢子是运动的,在皮肤中移动以寻找并进入血管,然后被带到肝脏。在这里,我们首次对体内的疟原虫孢子进行了描述,分析了它们在小鼠皮肤和人皮肤移植物中的运动,并将其与两种啮齿动物疟疾寄生虫的运动进行了比较。这些数据表明,与肝和血液阶段不同,皮肤并不是疟原虫的种特异性屏障。事实上,疟原虫孢子以类似于啮齿动物疟原虫的速度进入小鼠皮肤的血管。此外,我们证明针对孢子的抗体显著影响疟原虫孢子在小鼠皮肤中的运动能力。尽管孢子阶段是一种经过验证的疫苗靶标,但疫苗试验因缺乏良好的人类疟疾寄生虫动物模型而受到阻碍。下一代疫苗的临床前筛选将得益于我们在这里描述的体内平台,这将加快候选疫苗在人体疫苗试验前的淘汰。